We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

IMF Applauds FDA Approval of Ninlaro (Ixazomib) to Treat Myeloma
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

Click here for the replay of "Myeloma 101 - Updates on Treatment & Pain Management" teleconference
IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients.

European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
First Irreversible Proteasome Inhibitor for Relapsed Multiple Myeloma Approved in the European Union. Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months Longer Without Disease Progression Compared to Common Treatment Course.

Great news for myeloma patients: FDA approves daratumumab
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

Black Swan Research Initiative Continues to Take the Stage for Advances in Myeloma
n his blog this week, IMF Chairman Dr. Brian Durie reports on last week’s symposium on “New Developments in MRD Diagnostics,” held in Zurich, Switzerland by the ESLHO (European Scientific Foundation of Laboratory Hemato Oncology). Conference panelists included Dr. Durie, who discussed MRD (minimal residual disease) and its role in the IMF’s signature Black Swan Research Initiative (BSRI), and fellow BSRI investigators Drs. Alberto Orfao (in photo) and Bruno Paiva.

Watch the replay of the "Multiple Myeloma and VA Benefits" webinar
Learn more about strategies for veteran's to maxmize access to VA support with Raymond Gustavson, a Retired Rating Specialist (RVSR) on the VA Appeals team.

The Bad and the Good About Food, Cancer, and Longevity
In his blog this week, IMF Chairman Dr. Brian Durie discusses the media frenzy surrounding The World Health Organization (WHO) study that proposed red and processed meats could be linked to cancer. The WHO and its linked research group, the International Agency for Research on Cancer (IARC) classified bacon and hot dogs as “human carcinogens (Group 1).” That designation means they are causing cancer in the same way that tobacco and asbestos are classified as cancer-causing agents. There is more to this story than just the headlines however, and Dr. Durie explains more about what this study means HERE.

International Myeloma Foundation Scores Support in Takeda Oncology’s ‘3 Points for Patients’ Campaign Partnership with NBA’s Boston Celtics

Every 3-Point Basket Will Trigger a Donation for IMF Research and Education

IMF Builds Exciting New Collaborations in China
In his blog this week, IMF Chairman Dr. Brian Durie recaps the IMF team’s trip last week to China. “The future is definitely bright for new developments in China,” he writes. “There are many challenges, including access to care and costs, but there is a strong commitment to do the very best for patients with resources available.”

Is There Value or Risk in New Guidance on Myeloma Treatment?
In his blog, IMF Chairman Dr. Brian Durie comments on the myeloma treatment guidance issued last week by the National Comprehensive Cancer Network (NCCN). The NCCN says its “evidence blocks” approach will provide a tool to educate providers and patients about “efficacy, safety, and affordability” of treatments. It is just one of several recent efforts to evaluate and recommend specific cancer treatment paths. Dr. Durie weighs in on the relative merits and drawbacks of these efforts.

    next      view all